Biosimilar Vs. Biosimilar: Coherus Sues Amgen For Infringing Adalimumab Formulation Patents

Amgen’s manufacture in California of its biosimilar for the European market infringes three recently issued patents, says Coherus, which is considerably behind Amgen in developing its own copy of AbbVie’s Humira. Lawsuit highlights the key role that intellectual property is likely to play in protecting biosimilar formulations, one patent attorney says.